Close
Shraddha Dalwadi, MD, MBA
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Shraddha Dalwadi, MD, MBA
Shraddha Dalwadi, MD, MBA, is an assistant professor in the Department of Radiation Oncology at the University of Texas Health Science Center at San Antonio. She specializes in radiation oncology and primarily treats breast cancer, central nervous system diseases, and metastatic malignancies of any type at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, using modern, personalized radiotherapy techniques.
She enjoys working within a multidisciplinary team and empowering patients to make decisions about their care. She also has developed several research interests and is passionate about medical education.
Dalwadi is originally from Cleveland, Texas. She earned a combined MD/MBA at the Texas A&M Health Science Center College of Medicine and completed her residency at the Baylor College of Medicine.
Now enrolling patients in the following clinical trial:
NRG-BR007: De-Escalation of Breast Radiation (DEBRA) Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Gender
- Female
Languages Spoken
- English
- Gujarati
- Hindi
-
Credentials
Credentials
Positions
- Assistant Professor, Department of Radiation Oncology, University of Texas Health Science Center San Antonio
Certifications
- American Board of Radiology, Radiation Oncology
Education
- Medical School: Texas A&M Health Science Center College of Medicine, College Station, TX
- Residency: Baylor College of Medicine, Houston, TX
- Internship: University of Texas Health Science Center at Houston, Houston, TX
- Graduate: MBA, Texas A&M University Mays Business School, College Station, TX
- Undergraduate: BS, Psychology, Texas A&M University College of Liberal Arts, College Station, TX
- Locations & Contact
-
Research & Publications
Research & Publications
Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation
Dalwadi SM, Hunt A, Bonnen MD, Ghebre YT.
Novel Radiotherapy Technologies in the Treatment of Gastrointestinal Malignancies
Dalwadi SM, Herman JM, Das P, Holliday EB.
Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
Shi F, Yoder AK, Mach C, Dalwadi S, Anderson ML, Hall TR, Ludwig MS.
View All Publications - Shraddha Dalwadi, MD
-
Clinical Trials
Clinical Trials
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Shraddha Dalwadi, MD, MBA
APOBEC3 Expression in HPV-Related Malignancies as a Novel Biomarker of Response to Definitive Chemoradiation
This is a non-randomized biomarker study with the aim to evaluate the relationship between APOBEC3B (A3B) expression in primary head and neck cancers (HNC), anus, and cervix tumors and pathologic response to definitive chemoradiation therapy.
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Shraddha Dalwadi, MD, MBA
NRG-CC014: Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)
This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causing symptoms (asymptomatic). High-risk bone metastases are defined by their location (including hip, shoulder, long bones, and certain levels of the spine), or size (2 cm or larger).